Investor Relations

At Viro-Gen, our commitment is to empower humanity with the tools for safe and effective disease management. We have deployed some of the finest scientists in Virology, Biochemistry and Immunology to develop the world’s first isotekh, an immune system optimisation treatment. With the ever-growing threat to humanity of disease outbreaks, it is our mission at Viro-Gen to bring a solution to the world that is natural and based on the human body’s own intelligent design.

This mission has been supported by Johannesburg Stock Exchange-listed pharmaceutical, Adcock Ingram (www.adcock.com), that has supported Viro-Gen’s early-stage discovery.

The following milestones mark important value events in our development timeline:

Workstream

Location

Study Phase

CANCER

Brazil

Animal

DIABETES

South Africa

Animal

HIV

France

Animal

Acquirer

Target

Deal Date

Technology

Novo Nordisk

Novartis

IPO (Nasdaq)